CYP2B6 and glomerulonephritis: Our results showed that cyclophosphamide-treated glomerulonephritis patients had a 4-fold higher expression of CYP2B6 (2.07 ± 2.94 vs. 0.45 ± 0.5; p = 0.01) than mycophenolate-treated patients.